36 search results for: long-term
Assessing EoE: Monitoring Patients With EoE in Clinical Practice
Hear Dr. Ulrike von Arnim discuss the expert recommendations for monitoring patients with EoE in routine clinical practice.
CRSwNP: A Chronic Type 2 Inflammatory Disease
Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.
Scientific Advances in EoE and Impact on Clinical Practice
Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.
EoE Quest: Navigating the Patient Experience
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.
Piecing Together the Puzzle in Patients With EoE
In this hypothetical EoE patient case, learn about the different disease domains that are important in seeing the complete patient picture in EoE.
UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?
Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.
World Congress of Dermatology (WCD) 2023 | Singapore
Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
UEG 2025 | Understanding Type 2 Inflammation in EoE: A Case-Based Discussion
Profs. Greuter, Savarino, and Giordano discuss best practices for EoE identification, multidimensional EoE assessment, and transition of care.
ADVENT at EAACI PAAM 2025
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.
ESPGHAN 2024 | Clinical Management of EoE in Adolescents to Adulthood
Prof. Salvatore Oliva discusses the latest treatment options for adolescents and adults with EoE and the importance of effective transition of care.
Uncovering the Impact of Moderate COPD Exacerbations
Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.
What proportion of patients can achieve control in CRSwNP?
Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
